Patients Aged ≥65 Years with Metastatic Colon Cancer: Associations of Clinicopathological Factors, Skeletal Muscle Mass, and Inflammatory–Nutritional Indices with Survival
Year: 2026
Type: article
Study design: Observational Study
Abstract: Objective: Prognostic assessment in older patients with metastatic colon cancer remains challenging. This study aimed to evaluate the associations of clinicopathological characteristics, computed tomography (CT)-defined low skeletal muscle mass, and inflammatory–nutritional indices with overall survival (OS) and progression-free survival (PFS). Methods: This single-center study analyzed data from 141 patients aged ≥65 years who received first-line systemic therapy between 2020 and 2026. Skeletal muscle index was evaluated in 128 patients using pretreatment CT images. Survival outcomes were assessed using Kaplan–Meier analysis and multivariable Cox proportional hazards regression analysis. Results: The median age was 71 years, and 75.0% of evaluable patients had a low skeletal muscle mass. The median OS was 30.32 months (95% confidence interval [CI]: 26.60–34.05), while the median PFS was 10.28 months (95% CI: 8.59–11.98). Synchronous metastases (hazard ratio [HR] = 3.745), Grade 3 tumors (HR = 3.084), absence of metastasectomy (HR = 3.650), high Köhne risk (HR = 2.546) and elevated carbonhydrate antigen [CA19-9] levels (HR = 1.812) were independently associated with shorter OS. Body mass index (BMI) of ≥25 kg/m2 was associated with a lower risk of mortality (HR = 0.624). High Köhne risk (HR = 2.162), Grade 3 tumors (HR = 1.750), elevated carcinoembryonic antigen [CEA] levels (HR = 1.716) and elevated CA19-9 levels (HR = 1.579) were independently associated with shorter PFS. No statistically significant difference was found between low skeletal muscle mass and survival. Furthermore, none of the inflammatory–nutritional indices included in the key multivariable models maintained their independent prognostic significance. Conclusions: High Köhne risk, poor tumor differentiation, and elevated CA19-9 levels were independently associated with shorter OS and PFS in older patients with metastatic colon cancer. There was no statistically significant difference between low skeletal muscle mass and survival outcomes, while inflammatory–nutritional indices did not show independent prognostic significance in the key multivariable models. Further prospective studies involving larger patient populations are needed to confirm these results.
Source: Journal of Clinical Medicine
DOI: 10.3390/jcm15229020
Authors: Esma Yetim(Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Visualization, Writing – original draft, Writing – review & editing), Sevcan Genç, Murat Yakın(Data curation, Investigation, Methodology), Faruk Aksu(Data curation, Investigation, Methodology), Zişan Hayriye Yücel(Data curation, Investigation), Aytül Hande Yardımcı(Writing – review & editing), Nilüfer Bulut(Data curation, Investigation, Methodology), Gökmen Umut Erdem(Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Supervision, Visualization, Writing – original draft, Writing – review & editing)
Language: English
Subfield: Physiology (medical)
Field: Medicine
Domain: Health Sciences
Keywords: metastatic colon cancer, elderly patients, prognostic factors, skeletal muscle mass, skeletal muscle index, overall survival, progression-free survival, CA19-9, carcinoembryonic antigen, tumor grade, synchronous metastases, body mass index, first-line systemic therapy, sarcopenia, nutritional status, cancer cachexia
Open Access status: gold
Estimated APC paid: $3,137
OpenAlex ID: W7235874827
